TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2879-2889

  Liu, Lanxia ^a   Dong, Xia ^a   Zhu, Dunwan ^a   Song, Liping ^a   Zhang, Hailing ^a   Leng, Xigang G ^a  

^a INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

Author keywords

Cancer treatment; Gene therapy; Hepatoma; Nanoparticles; Targeted gene delivery

Indexed keywords

CHITOSAN; GONADORELIN; TRANSACTIVATOR PROTEIN; DNA; NANOCAPSULE; NANOCONJUGATE;

ARTICLE; ATOMIC FORCE MICROSCOPY; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE DELIVERY SYSTEM; GENE TARGETING; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VITRO STUDY; LIGHT SCATTERING; ZETA POTENTIAL; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; GENE THERAPY; GENETICS; MOLECULAR WEIGHT; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHITOSAN; DNA; GENE PRODUCTS, TAT; GENETIC THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MOLECULAR WEIGHT; NANOCAPSULES; NANOCONJUGATES; TREATMENT OUTCOME;

EID: 84902361992     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S61392     Document Type: Article

References (44)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002; 36(5 Suppl 1): S74-S83.
2. Bosch FX, de Sanjose S, Castellsague X. The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Cancer Discov. 2011;1(5):377-380.
3. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312-1327.
4. Li X, Pan Y, Fan R, et al. Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivo. Carcinogenesis. 2008;29(8):1587-1593.
5. Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008;195(6):829-836.
6. Deshpande R, O'Reilly D, Sherlock D. Improving outcomes with surgical resection and other ablative therapies in HCC. Int J Hepatol. 2011;2011:686074.
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917.
8. Levin B. Cancer prevention: new challenges and opportunities. Curr Opin Oncol. 1995;7(5):397.
9. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32(1 Suppl):225-237.
10. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37.
11. Arbuthnot P, Thompson LJ. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J Gastroenterol. 2008;14(11):1670-1681.
12. Panda JJ, Varshney A, Chauhan VS. Self-assembled nanoparticles based on modified cationic dipeptides and DNA: novel systems for gene delivery. J Nanobiotechnology. 2013;11:18.
13. Klutz K, Schaffert D, Willhauck MJ, et al. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther. 2011;19(4):676-685.
14. Cheng MR, Li Q, Wan T, et al. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol. 2012;18(42):6076-6087.
15. Meng L, Yang L, Zhao X, et al. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS One. 2012;7(4):e33434.
16. Minko T, Dharap SS, Fabbricatore AT. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense. Cancer Detect Prev. 2003;27(3):193-202.
17. Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release. 2003;91(1-2):61-73.
18. Minko T, Dharap SS, Pakunlu RI, Wang Y. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets. 2004;5(4):389-406.
19. Tang Q, Cao B, Wu H, Cheng G. Selective gene delivery to cancer cells using an integrated cationic amphiphilic peptide. Langmuir. 2012;28(46):16126-16132.
20. Dharap SS, Wang Y, Chandna P, et al. Tumor-specific targeting of ananticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005;102(36):12962-12967.
21. Yin H, Cheng KW, Hwa HL, Peng C, Auersperg N, Leung PC. Expression of the messenger RNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines. Life Sci. 1998;62(22):2015-2023.
22. Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anticancer Drugs. 2008;19(4):349-358.
23. MacLaughlin FC, Mumper RJ, Wang J, et al. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release. 1998;56(1-3):259-272.
24. Richardson SC, Kolbe HV, Duncan R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm. 1999; 178(2):231-243.
25. Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release. 2001;70(3):399-421.
26. Bloomfield VA. DNA condensation. Curr Opin Struct Biol. 1996;6(3): 334-341.
27. Malhotra M, Tomaro-Duchesneau C, Saha S, Kahouli I, Prakash S. Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int J Nanomedicine. 2013;8: 2041-2052.
28. Oliveira AV, Silva AP, Bitoque DB, Silva GA, Rosa da Costa AM. Transfection efficiency of chitosan and thiolated chitosan in retinal pigment epithelium cells: A comparative study. J Pharm Bioallied Sci. 2013;5(2):111-118.
29. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res. 1998;15(9):1332-1339.
30. Corsi K, Chellat F, Yahia L, Fernandes JC. Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials. 2003;24(7):1255-1264.
31. Cumber AJ, Forrester JA, Foxwell BM, Ross WC, Thorpe PE. Preparation of antibody-toxin conjugates. Methods Enzymol. 1985;112:207-225.
32. Milani R, Monogioudi E, Baldrighi M, et al. Hydrophobin: fluorosurfactant-like properties without fluorine. Soft Matter. 2013;9:6505-6514.
33. Bajaj G, Van Alstine WG, Yeo Y. Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release. PLoS One. 2012;7(1):e30899.
34. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515.
35. Xiao B, Wang X, Qiu Z, et al. A dual-functionally modified chitosan derivative for efficient liver-targeted gene delivery. J Biomed Mater Res A. 2013;101(7):1888-1897.
36. Liu L, Bai Y, Zhu D, et al. Evaluation of the impact of arginine-chitosan/DNA nanoparticles on human naive CD4+ T cells. J Biomed Mater Res A. 2011;96(1):170-176.
37. Buschmann MD, Merzouki A, Lavertu M, Thibault M, Jean M, Darras V. Chitosans for delivery of nucleic acids. Adv Drug Deliv Rev. 2013;65(9):1234-1270.
38. Li X-F, Feng X-Q, Yang S, Wang T-P, Su Z-X. Effects of molecular weight and concentration of chitosan on antifungal activity against Aspergillus niger. Iranian Polymer Journal. 2008;17(11):843-852.
39. Wedmore I, McManus JG, Pusateri AE, Holcomb JB. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma. 2006;60(3):655-658.
40. Garcia-Fuentes M, Alonso MJ. Chitosan-based drug nanocarriers: where do we stand? J Control Release. 2012;161(2):496-504.
41. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62(1):3-11.
42. Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004;21(2):344-353.
43. Düzgünes N, De Ilarduya CT, Simões S, et al. Cationic liposomes for gene delivery: novel cationic lipids and enhancement by proteins and peptides. Curr Med Chem. 2003;10(14):1213-1220.
44. Sato T, Ishii T, Okahata Y. In vitro gene delivery mediated by chitosan, effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials. 2001;22(15):2075-2080.